Supplementary Table 7 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Clinical information on the series of serum samples from CLL clinical patients exposed to idelalisib or to ibrutinib. Samples were longitudinally acquired at different time points. Patients were paired according to similar clinical features.